Diabetes　and　its　associated　secondary　complications　represent　significant　global　health　challenges.　This　study　aimed　to　address　these　issues　by　investigating　Fernandoa　adenophylla,　a　plant　utilized　in　various　alternative　medicine　systems　for　its　antidiabetic　properties.　Five　compounds　Lapachol　(1),　Alpha-lapachone　(2),　Peshawaraquinone　(3),　Dehydro-α-lapachone　(4),　and　Indanone　derivatives　(5)　were　isolated　from　this　plant　and　evaluated　for　their　aldose　reductase　inhibitory　potential.　Among　the　compounds　tested,　Alpha-lapachone　exhibited　the　highest　efficacy　with　an　inhibition　rate　of　86.4　%　and　an　IC50　value　of　1.4　±　0.5　μM,　followed　by　Peshawaraquinone　and　Lapachol,　which　demonstrated　inhibition　rates　of　82.9　%　and　81.6　%,　respectively.　Further　evaluations　of　these　compounds　included　pharmacokinetic　characterization　and　toxicity　profiling　using　SwissADME,　StopTox,　Molinspiration,　and　ProTox　3.0　tools.　Molecular　docking　studies　were　conducted　to　assess　the　interactions　between　the　bioactive　metabolites　of　F.　adenophylla　and　aldose　reductase.　Most　of　the　isolates　exhibited　notable　antidiabetic　properties,　with　the　phytochemicals　showing　promising　pharmacological　attributes　and　demonstrating　strong　binding　affinity　and　interactions　within　the　allosteric　site　of　the　target　protein　(PDB　ID:　3V36).　Among　the　compounds　investigated,　Alpha-lapachone　(2)　emerged　as　the　most　promising　candidate　for　drug　development,　pending　further　in　vivo　and　clinical　trials.　These　findings　underscore　the　potential　of　F.　adenophylla　for　clinical　applications　in　managing　diabetes　and　warrant　further　research　to　explore　its　therapeutic　possibilities.　©　2024